Skip to main navigation Skip to search Skip to main content

¿A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)¿

Project: Research project

Project Details

StatusFinished
Effective start/end date7/30/13 → 12/31/16

Funding

  • Bayer HealthCare Pharmaceuticals ( Award # ): $21,546.00